+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hereditary Angioedema Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

  • ID: 4911343
  • Report
  • November 2019
  • Region: Global
  • 184 pages
  • Transparency Market Research
1 of 3

FEATURED COMPANIES

  • Attune Pharmaceuticals
  • CSL Limited
  • Pharming Group N.V.
  • MORE
Hereditary Angioedema Treatment Market - Scope of the Report

the report on the global hereditary angioedema treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the market for the forecast period of 2019 to 2027. The report provides the overall market revenue of the global hereditary angioedema treatment market for the period of 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global hereditary angioedema treatment market for the forecast period.

The report has been prepared after extensive primary and secondary research. Primary research involved bulk of the research efforts, wherein, analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global hereditary angioedema treatment market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of the top-down and bottom-up approach to study various phenomena in the global hereditary angioedema treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the global hereditary angioedema treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global hereditary angioedema treatment market.

The report delves into the competitive landscape of the global hereditary angioedema treatment market. Key players operating in the global hereditary angioedema treatment market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the global hereditary angioedema treatment market that have been profiled in this report.

Key Questions Answered in the Hereditary Angioedema Treatment market Report
  • What is the sales/revenue expected to be generated by each drug class and route of administration segment of the hereditary angioedema treatment market across all regions during the forecast period?
  • What are the opportunities in the global hereditary angioedema treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is likely to expand at the fastest CAGR during the forecast period?
  • Which hereditary angioedema drug class, route of administration, and distribution channel segments are expected to generate the highest revenue, globally, in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What was the market share or position of different companies operating in the global market in 2018?
Global Hereditary Angioedema Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global hereditary angioedema treatment market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study, pipeline analysis, orphan drug exclusivity scenario, key mergers & acquisitions, and disease overview.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into small sections. The entire report comprises an exhaustive collection of graphs and tables appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Attune Pharmaceuticals
  • CSL Limited
  • Pharming Group N.V.
  • MORE
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hereditary Angioedema Treatment Market

4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook
5.1. Pipeline Analysis
5.2. Orphan Drug Exclusivity Scenario
5.3. Key Merger & Acquisitions
5.4. Disease Overview
5.5. Disease Prevalence-Global and Key Countries

6. Global Hereditary Angioedema Treatment Market Analysis and Forecast, by Drug Class, 2017–2027
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2027
6.3.1. C1 Esterase Inhibitor
6.3.1.1. Plasma Products
6.3.1.1.1. Berinert
6.3.1.1.2. Cinryze
6.3.1.1.3. Haegarda
6.3.1.2. Recombinant Products
6.3.1.2.1. Ruconest
6.3.2. Selective Bradykinin B2 Receptor Antagonist
6.3.2.1. Firazyr
6.3.3. Kallikrein Inhibitor
6.3.3.1. Kalbitor
6.3.3.2. Takhzyro
6.3.4. Others
6.3.4.1. Conventional Drugs
6.3.4.2. Pipeline Drugs
6.4. Market Attractiveness By Drug Class

7. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Route of Administration, 2017–2027
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2027
7.3.1. Intravenous
7.3.2. Subcutaneous Injection
7.3.3. Oral
7.4. Market Attractiveness, by Route of Administration

8. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Distribution Channel, 2017–2027
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2027
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Others
8.4. Market Attractiveness, by Distribution Channel

9. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Region, 2017–2027
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Rest of the World
9.3. Market Attractiveness, by Country/Region

10. North America Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2027
10.2.1. C1 Esterase Inhibitor
10.2.1.1. Plasma Products
10.2.1.1.1. Berinert
10.2.1.1.2. Cinryze
10.2.1.1.3. Haegarda
10.2.1.2. Recombinant Products
10.2.1.2.1. Ruconest
10.2.2. Selective Bradykinin B2 Receptor Antagonist
10.2.2.1. Firazyr
10.2.3. Kallikrein Inhibitor
10.2.3.1. Kalbitor
10.2.3.2. Takhzyro
10.2.4. Others
10.2.4.1. Conventional Drugs
10.2.4.2. Pipeline Drugs
10.3. Market Value Forecast, by Route of Administration, 2017–2027
10.3.1. Intravenous
10.3.2. Subcutaneous Injection
10.3.3. Oral
10.4. Market Value Forecast, by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country

11. Europe Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027
11.1. .Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2027
11.2.1. C1 Esterase Inhibitor
11.2.1.1. Plasma Products
11.2.1.1.1. Berinert
11.2.1.1.2. Cinryze
11.2.1.1.3. Haegarda
11.2.1.2. Recombinant Products
11.2.1.2.1. Ruconest
11.2.2. Selective Bradykinin B2 Receptor Antagonist
11.2.2.1. Firazyr
11.2.3. Kallikrein Inhibitor
11.2.3.1. Kalbitor
11.2.3.2. Takhzyro
11.2.4. Others
11.2.4.1. Conventional Drugs
11.2.4.2. Pipeline Drugs
11.3. Market Value Forecast, by Route of Administration, 2017–2027
11.3.1. Intravenous
11.3.2. Subcutaneous Injection
11.3.3. Oral
11.4. Market Value Forecast, by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region

12. Rest of the World Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2027
12.2.1. C1 Esterase Inhibitor
12.2.1.1. Plasma Products
12.2.1.1.1. Berinert
12.2.1.1.2. Cinryze
12.2.1.1.3. Haegarda
12.2.1.2. Recombinant Products
12.2.1.2.1. Ruconest
12.2.2. Selective Bradykinin B2 Receptor Antagonist
12.2.2.1. Firazyr
12.2.3. Kallikrein Inhibitor
12.2.3.1. Kalbitor
12.2.3.2. Takhzyro
12.2.4. Others
12.2.4.1. Conventional Drugs
12.2.4.2. Pipeline Drugs
12.3. Market Value Forecast, by Route of Administration, 2017–2027
12.3.1. Intravenous
12.3.2. Subcutaneous Injection
12.3.3. Oral
12.4. Market Value Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Route of Administration
12.5.3. By Distribution Channel

13. Competitive Landscape
13.1. Market Player - Competition Matrix (By Tier and Size of companies)
13.2. Market Share Analysis, by Company, 2018
13.3. Company Profiles
13.3.1. Shire plc (Takeda Pharmaceutical Company Limited)
13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.1.2. Company Financials
13.3.1.3. Growth Strategies
13.3.1.4. SWOT Analysis
13.3.2. CSL Limited
13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.2.2. Company Financials
13.3.2.3. Growth Strategies
13.3.2.4. SWOT Analysis
13.3.3. Pharming Group N.V.
13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.3.2. Company Financials
13.3.3.3. Growth Strategies
13.3.3.4. SWOT Analysis
13.3.4. Ionis Pharmaceuticals, Inc.
13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.4.2. Company Financials
13.3.4.3. Growth Strategies
13.3.4.4. SWOT Analysis
13.3.5. BioCryst Pharmaceuticals, Inc.
13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.5.2. Company Financials
13.3.5.3. Growth Strategies
13.3.5.4. SWOT Analysis
13.3.6. KalVista Pharmaceuticals Ltd.
13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.6.2. Company Financials
13.3.6.3. Growth Strategies
13.3.6.4. SWOT Analysis
13.3.7. Attune Pharmaceuticals
13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.7.2. Company Financials
13.3.7.3. Growth Strategies
13.3.7.4. SWOT Analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Shire plc (Takeda Pharmaceutical Company Limited)
  • CSL Limited
  • Pharming Group N.V.
  • Ionis Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals Ltd.
  • Attune Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll